PD-L1 在恶性涎腺肿瘤中的表达。
PD-L1 expression in malignant salivary gland tumors.
机构信息
Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
出版信息
BMC Cancer. 2018 Feb 6;18(1):156. doi: 10.1186/s12885-018-4069-3.
BACKGROUND
Programmed death-1 ligand-1 (PD-L1) an important cancer biomarker that can suppress the immune system and its high expression is often reported to be related with increased tumor aggressiveness in some cancers. Here, we examined and evaluated PD-L1 expression in patients with malignant salivary gland tumor. Moreover, the relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of malignant salivary gland tumors was investigated.
METHODS
We examined PD-L1expression in 47 patients with malignant salivary gland tumor by immunohistochemical staining. PD-L1 positivity was defined as ≥5% in tumor cell membrane and evaluated according to three categories (0% = 0, < 5% = 1, ≥5% = 2) in tumor-infiltrating mononuclear cells (TIMCs). Fisher's exact test was used to compare between PD-L1 expression and clinico-pathological features, and Kaplan-Meier method was used to estimate the distribution of OS by PD-L1 positivity.
RESULTS
PD-L1 expression was detected in 51.1% of malignant salivary gland tumor tissues. No association was observed between PD-L1 immunolocalization in tumor and patient gender, or age. However, PD-L1 immunodetection of tumor cell membranes was significantly associated to stage, recurrence or metastasis after surgery, and patient outcome. On the other hand, PD-L1 immunodetection of tumor-infiltrating mononuclear cells (TIMCs) was significantly associated to recurrence or metastasis after surgery, and patient outcome. PD-L1 positivity in both tumor cell membrane and TIMCs was associated with shorter overall survival (OS) (p = 0.002 and p = 0.016, respectively).
CONCLUSION
These findings suggested that patients with PD-L1 positive tumors or TIMCs appear to have poor clinical outcomes in malignant salivary gland tumors.
背景
程序性死亡配体-1（PD-L1）是一种重要的癌症生物标志物，可抑制免疫系统，其高表达常与某些癌症中肿瘤侵袭性增加有关。在这里，我们检查并评估了恶性涎腺肿瘤患者的 PD-L1 表达。此外，还研究了 PD-L1 免疫定位与临床病理特征以及恶性涎腺肿瘤预后之间的关系。
方法
我们通过免疫组织化学染色检查了 47 例恶性涎腺肿瘤患者的 PD-L1 表达。PD-L1 阳性定义为肿瘤细胞膜≥5%，并根据肿瘤浸润单核细胞（TIMC）中的三个类别（0%=0，<5%=1，≥5%=2）进行评估。Fisher 确切检验用于比较 PD-L1 表达与临床病理特征之间的关系，Kaplan-Meier 法用于估计 PD-L1 阳性的 OS 分布。
结果
在 51.1%的恶性涎腺肿瘤组织中检测到 PD-L1 表达。PD-L1 免疫组化在肿瘤中的定位与患者性别或年龄之间无关联。然而，肿瘤细胞膜的 PD-L1 免疫检测与肿瘤分期、手术后复发或转移以及患者预后显著相关。另一方面，肿瘤浸润单核细胞（TIMC）中的 PD-L1 免疫检测与手术后复发或转移以及患者预后显著相关。肿瘤细胞膜和 TIMC 中 PD-L1 阳性与总生存期（OS）较短相关（p=0.002 和 p=0.016）。
结论
这些发现表明，PD-L1 阳性肿瘤或 TIMC 患者在恶性涎腺肿瘤中似乎具有较差的临床结局。
Zotero 插件